PE20180530A1 - Derivados de amidas policiclicas como inhibidores de cdk9 - Google Patents
Derivados de amidas policiclicas como inhibidores de cdk9Info
- Publication number
- PE20180530A1 PE20180530A1 PE2017002874A PE2017002874A PE20180530A1 PE 20180530 A1 PE20180530 A1 PE 20180530A1 PE 2017002874 A PE2017002874 A PE 2017002874A PE 2017002874 A PE2017002874 A PE 2017002874A PE 20180530 A1 PE20180530 A1 PE 20180530A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- lymphoma
- tetrahydroimidazo
- carboxamide
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185852P | 2015-06-29 | 2015-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180530A1 true PE20180530A1 (es) | 2018-03-19 |
Family
ID=56292699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002874A PE20180530A1 (es) | 2015-06-29 | 2016-06-27 | Derivados de amidas policiclicas como inhibidores de cdk9 |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019058348A1 (en) | 2017-09-25 | 2019-03-28 | Astrazeneca Ab | COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER |
| WO2019074748A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PHENYL-OXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN114008046B (zh) * | 2019-06-27 | 2023-08-18 | 南京明德新药研发有限公司 | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 |
| WO2021050824A1 (en) | 2019-09-11 | 2021-03-18 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| EP4074699A4 (en) * | 2019-12-09 | 2024-01-03 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | COMPOUND USEFUL AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF |
| EP4140997A4 (en) * | 2020-05-12 | 2023-09-06 | Suzhou Alphama Biotechnology Co., Ltd. | PYRIDINE ACETAMIDE DERIVATIVE AS CDK INHIBITOR, PREPARATION METHOD AND USE THEREOF |
| EP4141004A4 (en) * | 2020-05-12 | 2023-08-23 | Suzhou Alphama Biotechnology Co., Ltd. | POLYCYCLIC AMIDE DERIVATIVE SERVING AS A CDK9 INHIBITOR, METHOD FOR PREPARING IT AND ITS USE |
| EP4171654A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
| US20230271942A1 (en) | 2020-08-07 | 2023-08-31 | Pharmablock Sciences (Nanjing), Inc. | Cdk9 inhibitor and use thereof |
| TWI809330B (zh) * | 2020-11-20 | 2023-07-21 | 大陸商勁方醫藥科技(上海)有限公司 | Cdk9抑制劑的多晶型物及其製法和用途 |
| WO2022247785A1 (zh) * | 2021-05-24 | 2022-12-01 | 石药集团中奇制药技术（石家庄）有限公司 | 一种周期蛋白依赖性激酶9抑制剂的用途 |
| CN115381824B (zh) * | 2021-05-24 | 2024-11-05 | 石药集团中奇制药技术（石家庄）有限公司 | 周期蛋白依赖性激酶9抑制剂的用途 |
| CN117813289A (zh) * | 2021-07-14 | 2024-04-02 | 上海海雁医药科技有限公司 | 吡唑衍生物及其中间体和制备方法 |
| CN115703738B (zh) * | 2021-08-16 | 2024-06-21 | 中国科学院上海药物研究所 | 含2-芳杂环取代的脲类化合物、其制备方法和用途 |
| JP2025501773A (ja) * | 2021-12-23 | 2025-01-23 | ザ・カトリック・ユニヴェルシテイト・ルーバン | Ｙａｐ／ｔａｚ－ｔｅａｄを阻害するためのテトラヒドロピラゾロピリミジン及び関連類似体 |
| JP2025528223A (ja) | 2022-08-17 | 2025-08-26 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | Ｃｄｋ２及び／又はｃｄｋ９の抑制又は分解用化合物及びこれらの医薬用途 |
| CN117659022A (zh) * | 2022-09-06 | 2024-03-08 | 苏州阿尔脉生物科技有限公司 | 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途 |
| US20240360075A1 (en) * | 2023-04-19 | 2024-10-31 | Alcon Inc. | N-substituted c6 cyclyl carboxamide compounds and uses thereof |
| WO2025076115A1 (en) * | 2023-10-02 | 2025-04-10 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| JP5379787B2 (ja) | 2007-04-24 | 2013-12-25 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
| WO2008129069A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| EP2137166B1 (en) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| ES2539518T3 (es) | 2007-04-24 | 2015-07-01 | Astrazeneca Ab | Inhibidores de proteínas quinasas |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| CN101889004B (zh) | 2007-10-12 | 2014-09-10 | 阿斯利康公司 | 蛋白激酶抑制剂 |
| EP2473502A1 (en) | 2009-09-04 | 2012-07-11 | Novartis AG | Heteroaryl compounds as kinase inhibitors |
| US20110113038A1 (en) | 2009-11-12 | 2011-05-12 | International Business Machines Corporation | Search term security |
| GB201002911D0 (en) | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
| KR20130016244A (ko) | 2010-03-10 | 2013-02-14 | 인게니움 파르마코이티칼스 게엠베하 | 단백질 키나아제의 억제제 |
| AR081810A1 (es) * | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| WO2012101062A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| UA114410C2 (uk) | 2011-10-06 | 2017-06-12 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mi)динілпіразол |
| JP2016516710A (ja) * | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系ｃｄｋ９キナーゼ阻害薬 |
| CA2901929A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Cdk9 kinase inhibitors |
| TW201446763A (zh) | 2013-03-14 | 2014-12-16 | Abbvie Inc | 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑 |
| AU2014244194A1 (en) | 2013-03-14 | 2015-09-10 | Abbvie Inc. | Pyrrolopyrimindine CDK9 kinase inhibitors |
-
2016
- 2016-06-27 SI SI201631427T patent/SI3539961T1/sl unknown
- 2016-06-27 CR CR20170596A patent/CR20170596A/es unknown
- 2016-06-27 JP JP2017567737A patent/JP6997627B2/ja active Active
- 2016-06-27 TR TR2019/09286T patent/TR201909286T4/tr unknown
- 2016-06-27 PE PE2017002874A patent/PE20180530A1/es unknown
- 2016-06-27 HR HRP20190748TT patent/HRP20190748T1/hr unknown
- 2016-06-27 SI SI201630247T patent/SI3313838T1/sl unknown
- 2016-06-27 LT LTEP19165726.1T patent/LT3539961T/lt unknown
- 2016-06-27 RS RS20220005A patent/RS62781B1/sr unknown
- 2016-06-27 LT LTEP16733459.8T patent/LT3313838T/lt unknown
- 2016-06-27 PL PL16733459T patent/PL3313838T3/pl unknown
- 2016-06-27 ES ES19165726T patent/ES2902148T3/es active Active
- 2016-06-27 PH PH1/2017/502334A patent/PH12017502334B1/en unknown
- 2016-06-27 HR HRP20211970TT patent/HRP20211970T1/hr unknown
- 2016-06-27 HU HUE19165726A patent/HUE057343T2/hu unknown
- 2016-06-27 PT PT16733459T patent/PT3313838T/pt unknown
- 2016-06-27 PL PL19165726T patent/PL3539961T3/pl unknown
- 2016-06-27 SM SM20190298T patent/SMT201900298T1/it unknown
- 2016-06-27 HU HUE16733459A patent/HUE043440T2/hu unknown
- 2016-06-27 MX MX2017016244A patent/MX371034B/es active IP Right Grant
- 2016-06-27 ES ES16733459T patent/ES2728356T3/es active Active
- 2016-06-27 CA CA2989499A patent/CA2989499C/en active Active
- 2016-06-27 SM SM20220005T patent/SMT202200005T1/it unknown
- 2016-06-27 TN TNP/2017/000486A patent/TN2017000486A1/en unknown
- 2016-06-27 EP EP16733459.8A patent/EP3313838B1/en active Active
- 2016-06-27 KR KR1020187002262A patent/KR102663113B1/ko active Active
- 2016-06-27 BR BR122019013677-7A patent/BR122019013677B1/pt active IP Right Grant
- 2016-06-27 ME MEP-2019-138A patent/ME03404B/me unknown
- 2016-06-27 WO PCT/EP2016/064899 patent/WO2017001354A1/en not_active Ceased
- 2016-06-27 CN CN201680029447.9A patent/CN107873028B/zh active Active
- 2016-06-27 EA EA201890094A patent/EA035383B1/ru not_active IP Right Cessation
- 2016-06-27 DK DK19165726.1T patent/DK3539961T3/da active
- 2016-06-27 EP EP19165726.1A patent/EP3539961B1/en active Active
- 2016-06-27 PT PT191657261T patent/PT3539961T/pt unknown
- 2016-06-27 US US15/193,826 patent/US9845331B2/en active Active
- 2016-06-27 MY MYPI2017705054A patent/MY201673A/en unknown
- 2016-06-27 CR CR20210297A patent/CR20210297A/es unknown
- 2016-06-27 RS RS20190564A patent/RS58712B1/sr unknown
- 2016-06-27 AU AU2016286200A patent/AU2016286200B2/en active Active
- 2016-06-27 DK DK16733459.8T patent/DK3313838T3/da active
- 2016-06-28 TW TW105120362A patent/TWI723028B/zh active
- 2016-06-28 AR ARP160101956A patent/AR105179A1/es unknown
-
2017
- 2017-12-06 US US15/833,277 patent/US10717746B2/en active Active
- 2017-12-12 DO DO2017000295A patent/DOP2017000295A/es unknown
- 2017-12-18 IL IL256393A patent/IL256393B/en unknown
- 2017-12-20 SV SV2017005598A patent/SV2017005598A/es unknown
- 2017-12-21 CL CL2017003306A patent/CL2017003306A1/es unknown
- 2017-12-22 NI NI201700174A patent/NI201700174A/es unknown
- 2017-12-28 CO CONC2017/0013713A patent/CO2017013713A2/es unknown
-
2018
- 2018-01-26 ZA ZA2018/00563A patent/ZA201800563B/en unknown
- 2018-09-25 DO DO2018000207A patent/DOP2018000207A/es unknown
-
2019
- 2019-06-19 CY CY20191100636T patent/CY1122111T1/el unknown
-
2020
- 2020-07-17 US US16/931,786 patent/US11352369B2/en active Active
-
2021
- 2021-12-22 CY CY20211101125T patent/CY1125066T1/el unknown
-
2022
- 2022-04-27 US US17/660,935 patent/US20220340592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180530A1 (es) | Derivados de amidas policiclicas como inhibidores de cdk9 | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
| CU24265B1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, útiles en el tratamiento del cáncer | |
| EA201790595A1 (ru) | Пиримидиноны в качестве ингибиторов фактора xia | |
| NZ749437A (en) | Processes and intermediates for making a jak inhibitor | |
| PE20160875A1 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| CL2017001422A1 (es) | Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas | |
| PH12015502047A1 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| NZ624068A (en) | Fused tricyclic compounds as raf kinase inhibitors | |
| MX2020013099A (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. | |
| EA201592082A1 (ru) | 3,4-дигидроизохинолин-2(1h)-ильные соединения | |
| EA201400182A1 (ru) | Производные пиридин-2(1н)-она в качестве ингибиторов jak | |
| HK1254469A1 (zh) | 稠合双环嘧啶衍生物及其用途 | |
| UA112795C2 (uk) | Біциклічні піразинонові похідні | |
| PE20110549A1 (es) | EL COMPUESTO 3-(4-CLORO-2-FLUOROBENCIL)-2-METIL-N-(5-METIL-1H-PIRAZOL-3-IL)-8-(MORFOLINOMETIL)IMIDAZO[1,2-b]PIRIDAZIN-6-AMINA, SUS SALES Y LA COMPOSICION QUE LO COMPRENDE | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| CY1122514T1 (el) | Σουλφονικος υδροξυαιθυλεστερας του αναστολεα της εξαρτωμενης απο κυκλινη πρωτεϊνικης κινασης, κρυσταλλικη μορφη αυτου και μεθοδος παρασκευης αυτου | |
| MX378932B (es) | Triazoles sustituidos y métodos relacionados a estos. | |
| AR106830A1 (es) | Usos de piridazinonas para tratar el cáncer | |
| EA201791881A1 (ru) | Производные 2-аминопиридина в качестве антагонистов рецептора аденозина aи лигандов рецепторов мелатонина mt | |
| HK1227872A1 (en) | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |